Immunome, Inc. Stock 12‑Month Price Target Raised to $36.15, Implies 38% Upside

Analysts have raised the average 12-month price target for Immunome, Inc. (IMNM) stock to $36.15, up from $35.77, with forecasts ranging from $30 to $40 per share. This new target suggests a potential upside of approximately 38% based on the August 11 closing price. The consensus rating from 14 analysts remains a "Buy," with no "Holds" or "Sells."